ConforMIS Inc (NASDAQ:CFMS) CEO Mark A. Augusti sold 6,807 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $3.53, for a total value of $24,028.71. Following the completion of the sale, the chief executive officer now owns 1,116,891 shares of the company’s stock, valued at $3,942,625.23. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of NASDAQ:CFMS traded down $0.13 during trading on Friday, reaching $3.42. 915,954 shares of the company traded hands, compared to its average volume of 1,356,713. The company has a market cap of $240.24 million, a price-to-earnings ratio of -4.62 and a beta of 3.05. The company has a debt-to-equity ratio of 0.64, a quick ratio of 2.33 and a current ratio of 3.00. ConforMIS Inc has a 52 week low of $0.36 and a 52 week high of $3.84.
ConforMIS (NASDAQ:CFMS) last released its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). The firm had revenue of $20.64 million during the quarter, compared to the consensus estimate of $20.11 million. ConforMIS had a negative return on equity of 97.85% and a negative net margin of 42.90%. Research analysts predict that ConforMIS Inc will post -0.43 EPS for the current fiscal year.
CFMS has been the subject of several recent research reports. Zacks Investment Research upgraded ConforMIS from a “sell” rating to a “hold” rating in a research note on Tuesday, March 5th. Oppenheimer boosted their price target on ConforMIS from $2.50 to $3.50 and gave the company an “outperform” rating in a research note on Tuesday, April 2nd. Finally, BTIG Research restated a “buy” rating and issued a $3.00 price target on shares of ConforMIS in a research note on Thursday, May 2nd. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $3.00.
WARNING: This piece was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://dakotafinancialnews.com/2019/05/18/mark-a-augusti-sells-6807-shares-of-conformis-inc-cfms-stock.html.
ConforMIS Company Profile
Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.
Featured Article: How to track put option volume
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.